Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C24H47NO3 |
Molecular Weight | 397.6349 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCCCCCCCCC\C=C\[C@@H](O)[C@H](CO)NC(=O)CCCCC
InChI
InChIKey=NPRJSFWNFTXXQC-QFWQFVLDSA-N
InChI=1S/C24H47NO3/c1-3-5-7-8-9-10-11-12-13-14-15-16-18-19-23(27)22(21-26)25-24(28)20-17-6-4-2/h18-19,22-23,26-27H,3-17,20-21H2,1-2H3,(H,25,28)/b19-18+/t22-,23+/m0/s1
Molecular Formula | C24H47NO3 |
Molecular Weight | 397.6349 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 1 |
Optical Activity | UNSPECIFIED |
N-hexanoylsphingosine is biologically active, cell permeable but nonphysiologic ceramide analog. Liposomal N-hexanoylsphingosine activates protein phosphatase 1 to inhibit melanoma cells. N-hexanoylsphingosine activates a cytosolic serine/threonine protein phosphatase in a dose-dependent manner. It induces cytochrome c (Cyt c) release from isolated rat liver mitochondria. It sensitizes vincristine-induced anticancer activity in vivo and in vitro, involving activating AMPK-p53 signaling.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P63331 Gene ID: 103694903|||24672 Gene Symbol: Ppp2ca Target Organism: Rattus norvegicus (Rat) Sources: https://www.ncbi.nlm.nih.gov/pubmed/8393446 |
|||
Target ID: map04210 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21935601 |
|||
Target ID: CHEMBL2164 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27631768 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Involvement of growth differentiation factor-15/macrophage inhibitory cytokine-1 (GDF-15/MIC-1) in oxLDL-induced apoptosis of human macrophages in vitro and in arteriosclerotic lesions. | 2004 Nov |
|
De novo ceramide biosynthesis is associated with resveratrol-induced inhibition of ornithine decarboxylase activity. | 2007 Jul 15 |
|
A role for ceramide in driving cancer cell resistance to doxorubicin. | 2008 Jul |
|
ABCB1 protects kidney proximal tubule cells against cadmium-induced apoptosis: roles of cadmium and ceramide transport. | 2011 Jun |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26116623
Mice: 15 mg C6 ceramide/5 ml saline/kg every two days for a total of 20 days
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7836432
A short chain synthetic ceramide, N-hexanoylsphingosine, was employed to treat Molt-4 cells in the presence of serum. Addition of N-hexanoylsphingosine not only caused programmed cell death, it also induced significant cell cycle arrest. N-hexanoylsphingosine-induced cell cycle arrest occurred rapidly (within 4 h) and doses as low as 15 uM N-hexanoylsphingosine (approximately 4 nM/10(6) cells) were able to reproduce effects reminiscent of prolonged serum deprivation: almost complete G0/G1 arrest following 14 h of treatment.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:48:20 GMT 2023
by
admin
on
Fri Dec 15 15:48:20 GMT 2023
|
Record UNII |
038753E78J
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
038753E78J
Created by
admin on Fri Dec 15 15:48:20 GMT 2023 , Edited by admin on Fri Dec 15 15:48:20 GMT 2023
|
PRIMARY | |||
|
C101954
Created by
admin on Fri Dec 15 15:48:20 GMT 2023 , Edited by admin on Fri Dec 15 15:48:20 GMT 2023
|
PRIMARY | |||
|
124753-97-5
Created by
admin on Fri Dec 15 15:48:20 GMT 2023 , Edited by admin on Fri Dec 15 15:48:20 GMT 2023
|
PRIMARY | |||
|
63867
Created by
admin on Fri Dec 15 15:48:20 GMT 2023 , Edited by admin on Fri Dec 15 15:48:20 GMT 2023
|
PRIMARY | |||
|
038753E78J
Created by
admin on Fri Dec 15 15:48:20 GMT 2023 , Edited by admin on Fri Dec 15 15:48:20 GMT 2023
|
PRIMARY | |||
|
1603859
Created by
admin on Fri Dec 15 15:48:20 GMT 2023 , Edited by admin on Fri Dec 15 15:48:20 GMT 2023
|
PRIMARY | |||
|
655091
Created by
admin on Fri Dec 15 15:48:20 GMT 2023 , Edited by admin on Fri Dec 15 15:48:20 GMT 2023
|
PRIMARY | |||
|
5702613
Created by
admin on Fri Dec 15 15:48:20 GMT 2023 , Edited by admin on Fri Dec 15 15:48:20 GMT 2023
|
PRIMARY | |||
|
DTXSID90924923
Created by
admin on Fri Dec 15 15:48:20 GMT 2023 , Edited by admin on Fri Dec 15 15:48:20 GMT 2023
|
PRIMARY |